{"entity":{"id":"pi3k-pikk-inhibitor-payloads","kind":"term","name":"PI3K/PIKK inhibitor payloads","aka":["HMPL-A580 payload","PI3K/PIKK antibody-targeted therapy conjugates"],"tldr":"These payloads block enzymes that support cancer-cell growth and stress responses. Antibody delivery is being studied as a way to direct those effects toward tumors.","summary":"The primary AACR abstract for HMPL-A580 describes an EGFR-directed antibody carrying a PI3K/PIKK inhibitor through a cleavable linker. Cell and xenograft experiments reported intracellular delivery, pathway inhibition and antitumor activity. PI3K and PIKK denote different kinase families; this broad payload label must not be reduced to a single selective kinase target without supporting data. The cited evidence is a preclinical conference abstract, not a clinical efficacy report.","asOf":"2026-11-08","links":[{"label":"Cai et al., HMPL-A580 preclinical AACR abstract (2026)","url":"https://doi.org/10.1158/1538-7445.AM2026-4549"}],"tags":[],"related":[],"cancers":[],"sections":[],"technologies":["adc"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["payload"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"category":"ADC chemistry"},"route":"/terms/pi3k-pikk-inhibitor-payloads/","neighbours":{"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"term":[{"id":"next-generation-adc-payloads","kind":"term","name":"Next-generation antibody-conjugate payloads","route":"/terms/next-generation-adc-payloads/"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/"}]}}